Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer

Marine Drugs

Volumn 13, Issue 6, 2015, Pages 3276-3286

  Cristóbal, Ion ^a   González Alonso, Paula ^a   Daoud, Lina ^a   Solano, Esther ^a   Torrejón, Blanca ^a   Manso, Rebeca ^a   Madoz Gúrpide, Juan ^a   Rojo, Federico ^a   García Foncillas, Jesús ^a  

^a 28400 Madrid   (Spain)

Author keywords

CIP2A; Okadaic acid; P PP2A; Prostate cancer; Therapy

Indexed keywords

FINGOLIMOD; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN CIP2A; PROTEIN KINASE B; PROTEIN SET; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN PHOSPHATASE 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLFORSIN; FINGOLIMOD HYDROCHLORIDE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; OKADAIC ACID; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN PHOSPHATASE 2;

EID: 84936084869     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13063276     Document Type: Article

References (24)

1. Westermarck, J.; Hahn, W.C. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 2008, 14, 152-160.
2. Mumby, M. PP2A: Unveiling a reluctant tumor suppressor. Cell 2007, 130, 21-24.
3. Janssens, V.; Goris, J.; van Hoof, C. PP2A: The expected tumor suppressor. Curr. Opin. Genet. Dev. 2005, 15, 34-41.
4. Eichhorn, P.J.; Creyghton, M.P.; Bernards, R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 2009, 1795, 1-15.
5. Bhardwaj, A.; Singh, S.; Srivastava, S.K.; Arora, S.; Hyde, S.J.; Andrews, J.; Grizzle, W.E.; Singh, A.P. Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br. J. Cancer 2014, 110, 2000-2010.
6. Bhardwaj, A.; Singh, S.; Srivastava, S.K.; Honkanen, R.E.; Reed, E.; Singh, A.P. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: Therapeutic implications. Mol. Cancer Ther. 2011, 10, 720-731.
7. Pandey, P.; Seshacharyulu, P.; Das, S.; Rachagani, S.; Ponnusamy, M.P.; Yan, Y.; Johansson, S.L.; Datta, K.; Fong Lin, M.; Batra, S.K. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br. J. Cancer 2013, 108, 2590-2600.
8. Bluemn, E.G.; Spencer, E.S.; Mecham, B.; Gordon, R.R.; Coleman, I.; Lewinshtein, D.; Mostaghel, E.; Zhang, X.; Annis, J.; Grandori, C.; et al. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol. Cancer Res. 2013, 11, 568-578.
9. Vaarala, M.H.; Va¨isa¨nen, M.R.; Ristima¨ki, A. CIP2A expression is increased in prostate cancer. J. Exp. Clin. Cancer Res. 2010, 29, 136.
10. Guo, Z.; Liu, D.; Su, Z. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway. Tumour Biol. 2015, in press.
11. Huang, J.; Jia, J.; Tong, Q.; Liu, J.; Qiu, J.; Sun, R.; Yao, L.; Yang, C. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy. Tumour Biol. 2014, 36, 1589-1594.
12. Corcoran, N.M.; Hovens, C.M.; Michael, M.; Rosenthal, M.A.; Costello, A.J. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br. J. Cancer 2010, 103, 462-468.
13. Kim, S.W.; Kim, H.J.; Chun, Y.J.; Kim, M.Y. Ceramide produces apoptosis through induction of p27(KIP1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. J. Toxicol. Environ. Health A 2010, 73, 1465-1476.
14. Kar, S.; Palit, S.; Ball, W.B.; Das, P.K. Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 2012, 17, 735-747.
15. Cirak, Y.; Varol, U.; Atmaca, H.; Kisim, A.; Sezgin, C.; Karabulut, B.; Uzunoglu, S.; Uslu, R.; Karaca, B. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU Int. 2012, 110 (11 Pt C), E1147-E1154.
16. Hung, C.M.; Su, Y.H.; Lin, H.Y.; Lin, J.N.; Liu, L.C.; Ho, C.T.; Way, T.D. Demethoxycurcumin modulates prostate cancer cell proliferation via AMPK-induced down-regulation of HSP70 and EGFR. J. Agric. Food Chem. 2012, 60, 8427-8434.
17. Cristóbal, I.; Garcia-Orti, L.; Cirauqui, C.; Alonso, M.M.; Calasanz, M.J.; Odero, M.D. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011, 25, 606-614.
18. Cristóbal, I.; Manso, R.; Rincón, R.; Caramés, C.; Senin, C.; Borrero, A.; Martínez-Useros, J.; Rodríguez, M.; Zazo, S.; Aguilera, O.; et al. PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential. Mol. Cancer Ther. 2014, 13, 938-947.
19. Rincón, R.; Cristóbal, I.; Zazo, S.; Arpí, O.; Menéndez, S.; Manso, R.; Lluch, A.; Eroles, P.; Rovira, A.; Albanell, J.; et al. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget 2015, 6, 4299-4314.
20. Perrotti, D.; Neviani, P. Protein phosphatase 2A: A target for anticancer therapy. Lancet Oncol. 2013, 14, e229-e238.
21. Farrell, A.S.; Allen-Petersen, B.; Daniel, C.J.; Wang, X.; Wang, Z.; Rodriguez, S.; Impey, S.; Oddo, J.; Vitek, M.P.; Lopez, C.; et al. Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer. Mol. Cancer Res. 2014, 12, 924-939.
22. Baldacchino, S.; Saliba, C.; Petroni, V.; Fenech, A.G.; Borg, N.; Grech, G. Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. EPMA J. 2014, 5, doi:10.1186/1878-5085-5-3.
23. Tonelli, F.; Lim, K.G.; Loveridge, C.; Long, J.; Pitson, S.M.; Tigyi, G.; Bittman, R.; Pyne, S.; Pyne, N.J. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal. 2010, 22, 1536-1542.
24. Tonelli, F.; Alossaimi, M.; Williamson, L.; Tate, R.J.; Watson, D.G.; Chan, E.; Bittman, R.; Pyne, N.J.; Pyne, S. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. Br. J. Pharmacol. 2013, 168, 1497-1505.